This finding drew the attention of Satoko Tsunokake et al., who analyzed the expression levels of SGLT1 and SGLT2 in patients with breast carcinoma and assessed how SGLT1 inhibitors affect neoplastic cells in vitro. The gene discussed is SLC5A1; the disease is breast carcinoma.